
    
      This is a randomized, multicenter, open-label, active-controlled study of the treatment of
      anemia in subjects with CKD on dialysis. Eligible subjects are randomized to FG-4592 or
      epoetin alfa at a ratio of 2:1. The primary endpoint is Hb mean change from baseline averaged
      over Weeks 23 to 27.
    
  